{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Iobenguane+I+123+Injection",
    "query": {
      "intervention": "Iobenguane I 123 Injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T10:44:39.482Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02656329",
      "title": "International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Iobenguane I -123 Injection",
          "type": "DRUG"
        },
        {
          "name": "Implantable Cardioverter Defibrillator",
          "type": "DEVICE"
        },
        {
          "name": "Thyroid blocking",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2015-12-30",
      "completion_date": "2018-05-04",
      "has_results": true,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02656329"
    },
    {
      "nct_id": "NCT01936649",
      "title": "Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure (HF)",
        "Ventricular Dysfunction, Left"
      ],
      "interventions": [
        {
          "name": "AdreView (Iobenguane I 123 Injection)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2013-08",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2016-12-08",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01936649"
    },
    {
      "nct_id": "NCT04510311",
      "title": "Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "3-[18F]Fluoro-para-hydroxyphenethylguanidine",
          "type": "DRUG"
        },
        {
          "name": "[123I] metaiodobenzylguanidine",
          "type": "DRUG"
        },
        {
          "name": "Positron emission tomography/computed tomography scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Planar scintigraphy scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Single photon emission computed tomography/computed tomography scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-10-19",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04510311"
    },
    {
      "nct_id": "NCT01432626",
      "title": "Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Induced Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "I-123 radiolabeled metaiodobenzylguanidine cardiac imaging",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-09",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432626"
    },
    {
      "nct_id": "NCT00730444",
      "title": "Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Iobenguane I 123 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-11-09",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730444"
    },
    {
      "nct_id": "NCT00126412",
      "title": "Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pheochromocytoma",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "123I-mIBG (meta-iodobenzylguanidine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 251,
      "start_date": "2005-08-02",
      "completion_date": "2006-09-27",
      "has_results": false,
      "last_update_posted_date": "2019-05-31",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126412"
    },
    {
      "nct_id": "NCT01250912",
      "title": "Imaging With a Radio Tracer to Guide VT Ablations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ventricular Tachycardia",
        "Arrhythmia"
      ],
      "interventions": [
        {
          "name": "123I-metaiodobenzylguanidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-03",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-01-27",
      "last_synced_at": "2026-09-14T10:44:39.482Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250912"
    }
  ]
}